Clinical Trials Logo
  1. Home
  2. Ovarian Neoplasm Epithelial
  3. NCT03509246

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

High Grade Serous Carcinoma Clinical Trial

Official title:
A Phase II Trial to Evaluate the Efficacy of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer

Clinical Trial Summary

This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade serous carcinoma without BRCA mutation among patients with platinum-resistant recurrent ovarian cancer.

Clinical Trial Description

Subjects are dosed with Bortezomib and PLD for a maximum of 6 cycles of 4 weeks. The response rate is evaluated with CT according to RECIST criteria ver 1.1. The efficacy and safety of the drug are assessed at the time of recurrence, at the time of death, or after 24 months after the end of the study drug administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03509246
Study type Interventional
Source Seoul National University Hospital
Contact Kidong Kim
Phone 82-31-787-7262
Email kidong.kim.md@gmail.com
Status Recruiting
Phase Phase 2
Start date May 15, 2018
Completion date March 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05537844 - Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
Recruiting NCT05358639 - Combination of Olaparib and Navitoclax in Women With HGSC and TNBC Phase 1
Recruiting NCT03738319 - Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
Recruiting NCT05080556 - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Phase 2
Recruiting NCT03462342 - Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer Phase 2
Withdrawn NCT05390021 - PET/MRI in Endometrial Cancer N/A
Terminated NCT04598321 - BrUOG 390: Neoadjuvant Treatment With Talazoparib Phase 1
Completed NCT05490407 - Role of the ATP7A Transporter in Ovarian Cancer N/A
Recruiting NCT04846933 - Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
Completed NCT03593681 - Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Terminated NCT03824704 - A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Phase 2